Allysta Pharmaceuticals, Inc.
Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical company focused on developing innovative medicines for rare diseases with high unmet needs. They are science-driven and results-focused, developing first-in-class therapeutic peptides with multiple biological actions, including anti-fibrotic, anti-inflammatory, cell regenerative, and beneficial metabolic effects. Their lead drug, ALY688ER, is a potent activator of adiponectin signaling pathways, with potential applications across multiple diseases, especially Duchenne muscular dystrophy (DMD). The company is also developing ALY688 ophthalmic solutions for eye injuries and other indications.
Industries
Nr. of Employees
small (1-50)
Allysta Pharmaceuticals, Inc.
Products
Sustained-release subcutaneous formulation of adiponectin-mimetic peptide
A systemic, sustained-release subcutaneous formulation of an adiponectin-mimetic peptide developed for extended delivery to target inflammation and fibrosis across multiple organs.
Topical ophthalmic formulation of adiponectin-mimetic peptide
An ophthalmic eye-drop formulation of an adiponectin-mimetic peptide intended to accelerate corneal epithelial healing and reduce ocular damage after chemical or toxic exposure.
Sustained-release subcutaneous formulation of adiponectin-mimetic peptide
A systemic, sustained-release subcutaneous formulation of an adiponectin-mimetic peptide developed for extended delivery to target inflammation and fibrosis across multiple organs.
Topical ophthalmic formulation of adiponectin-mimetic peptide
An ophthalmic eye-drop formulation of an adiponectin-mimetic peptide intended to accelerate corneal epithelial healing and reduce ocular damage after chemical or toxic exposure.
Services
Internal clinical development and program management
In-house program management and clinical operations supporting design and conduct of the company's development programs through early- and mid-stage clinical trials.
Internal clinical development and program management
In-house program management and clinical operations supporting design and conduct of the company's development programs through early- and mid-stage clinical trials.
Expertise Areas
- Peptide therapeutics development
- Preclinical disease modeling of fibrosis and inflammation
- Formulation development (sustained-release and ophthalmic)
- Clinical trial management (ophthalmology and systemic indications)
Key Technologies
- Synthetic peptide therapeutics
- Adiponectin receptor agonists / adiponectin-mimetic signaling
- Sustained-release subcutaneous formulations
- Ophthalmic solution formulations (topical eye drops)